Tracks how patients with obstructive hypertrophic cardiomyopathy feel on mavacamten
Follows adults with a heart thickening condition who take mavacamten in everyday care.
Plain-language title generated from the registry record
Registry title: Real-world Patient Reported Outcomes Among Patients Treated With Camzyos
Key facts
- Where
- Boston, United StatesSee the site
Where in United States
- Analysis Group, Inc.Boston, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT06551129
- Record updated
- 7 November 2024
- Original description
This real-world study will assess changes in health status among participants with symptomatic obstructive hypertrophic cardiomyopathy who are treated with mavacamten in the real world.Read full original descriptionShow less
Real-World Camzyos Patient Reported OutcoMes Through PAtient SurveyS in Hypertrophic CardioMyopathy (COMPASS-HCM): A Prospective Longitudinal Study
This real-world study will assess changes in health status among participants with symptomatic obstructive hypertrophic cardiomyopathy who are treated with mavacamten in the real world.
Inclusion: Participants ≥18 years of age; Participants who are prescribed mavacamten for obstructive hypertrophic cardiomyopathy; Provided informed consent to participate in the study.
Exclusion: Previously or currently enrolled in clinical trials for any cardiac myosin inhibitors; Enrolled in any clinical trials at the time of or within the six-month period prior to the screening; Had heart attack requiring coronary artery bypass grafting within the three-month period prior to the screening; Had stroke or transient ischemic attack within the six-month period prior to the screening; Had major lung (thoracic) or heart (cardiac) surgery within the six-month period prior to the screening; Hospitalized requiring an overnight stay at the time of or within the two-week period prior to the screening; Had moderate-to-severe lung disease which impacted the ability to perform daily activities of living and ability to breathe; Scheduled for a major surgery for the next three months, such as joint surgeries including hip replacement, abdominal surgeries, lung surgeries, heart surgeries, eye surgeries, brain surgeries, and any other major surgeries that require general anesthesia and at least an overnight hospital stay; Treated for >7 days with mavacamten by the day of completing the baseline survey.